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calculated deformation fields that can be applied to dose matrices. 
This allows us to accumulate the dose from one brachytherapy 
fraction to the next and will provide an improved estimate of the 
total dose delivered to the OAR. It should however be kept in mind 
that without a robust validation procedure,results could be very 
wrong in view of the very high dose gradients involved.The 
development of such a procedure should consequently be a 
prerequisite to any use of the deformation for brachytherapy in the 
clinic. 
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Purpose/Objective: The MR compatible Vienna (tandem-ring) and 
Utrecht applicator (tandem-ovoids) can be used for combined 
intracavitary (IC) and interstitial (IS) brachytherapy (BT) of locally 
advanced cervical cancer, with needles inserted through holes in the 
ring or ovoids. Recently a novel titanium Rotterdam applicator 
(tandem-ovoids) (Nucletron, Elekta) has been introduced which is well 
suited for MR guided IC BT of cervical cancer. This applicator has a 
fixed geometry and therefore enables fast and accurate applicator 
reconstruction. Currently the Rotterdam applicator does not include 
holes in the ovoids for needle positioning. The configuration of the 
holes restricts the possible locations and directions of needles. 
Therefore, the holes in the ovoids should be positioned such to allow 
optimal needle positioning for every patient. The purpose of this study 
is to determine the optimal configuration of the holes for needle 
positioning in the ovoids of the Rotterdam applicator making it 
suitable for combined IC/IS BT. 
Materials and Methods: A planning study was performed using MR 
datasets of 4 randomly chosen patients receiving IC BT for cervical 
cancer using the Rotterdam applicator. HR-CTV (range 1.2 – 57.5 cc), 
IR-CTV, rectum, sigmoid and bladder were delineated. The applicator 
was reconstructed with the aid of the applicator library file, a digital 
model of the applicator, present in the treatment planning system. 
For the IC treatment, without interstitial needles, modification of the 
standard treatment plan, that prescribes 7 Gy in points A, was 
necessary for all cases in order to restrict the dose to the OARs. The 
optimal position and direction of the ovoid holes for needle 
positioning was studied by adding virtual holes to the applicator 
library file at different locations and directions. This way treatment 
plans could be optimized for different needle (hole) configurations 
aiming at an increase of the dose to the HR-CTV while limiting the 
dose to the OARs. The configuration that yielded the best results 
among the 4 patients will be used as a blueprint for the holes in a 
prototype of the new applicator. 
Results: When using the IC applicator alone without needles, the dose 
in points A needed to be reduced from 7 Gy to 4.9 - 6.7 Gy. This 
resulted in a coverage of the delineated HR-CTV of (only) 66.5, 60.0, 
82.3 and 100.0 %, respectively, with a D90 HR-CTV of 4.9, 7.0, 5.9 and 
9.8 Gy. It turned out that a geometry allowing for insertion of 
maximally 3 needles per ovoid, each having an angle of 15º with the 
tandem in ventral-dorsal direction, resulted in a considerable increase 
of the D90 HR-CTV. For this geometry the coverage of the HR-CTV was 
88.1, 99.7, 98.6 and 100.0 %, respectively. The D90 HR-CTV was 6.7, 
9.5, 9.4 and 10.2 Gy. 
Conclusions: We have studied the optimal configuration of holes in 
the ovoids of the Rotterdam applicator for needle positioning for 
combined IC/IS treatment of locally advanced cervical cancer. A 
prototype of this new applicator is being build.  
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Purpose/Objective: The effect of bladder fullness on dose-volume 
parameters of OARs during the HDR intracavitary brachytherapy 
procedure with tandem-ovoid applicators and 192Ir source have been 
studied for cervical cancer patients who had complete response after 
EBRT. 
Materials and Methods: 17 patients with various cervical cancer 
stages with good remission of tumor after treating by 45-50 Gy 
external beam (there was no sign of residual tumor in taking MRIs 
after external beam treatment) took intracavitary Brachytherapy by 
Rotterdam Tandem-Ovoids applicators undergone two set of CT scans 
consecutively, one with filling the bladder by 120cc of normal saline 
solution and 3cc Meglumin compound and the other one with making 
the bladder as empty as possible, by trying to have no intended body 
motion during acquisitions. 3D image reconstruction has been done, 
and after that HR-CTV and OARs contouring applied, on the bases of 
GEC-ESTRO recommendations, for both CT sets. Finally 3D treatment 
planning has been achieved by the optimization capability of the 
software and exertion of manual corrections for dwell positions and 
times. 
Results: The volume of full and empty bladders was 166.5±26.4 and 
61.0±18.5, respectively. Paired samples T-test (P value=0.05) was 
used and the result have been indicated that there is no significant 
difference in D (2 cc), D (0.1 cc) and D (1 cc) of bladder, and also, D 
(2 cc) and D (0.1 cc) of rectum and sigmoid (p>0.05). Although, 
getting average of these dose parameters values respect to prescribe 
dose has shown a reduction for empty bladder condition. Mean 
Percentage Difference of CTV volumes were in the range of 0.00-0.08 
for two groups of contouring the patients CTs.  
 
 Mean value (percentage of prescribed dose)  
p-
value 
Empty bladder (%) Full bladder (%)   
0.098 74.2 82.7 
D (2cc) 
Bladder 
0.535 66.9 68.2 Rectum
0.830 46.8 47.4 Sigmoid
0.098 82.1 91.5 D (1cc) Bladder
0.055 100.6 117.6 
D
(0.1cc) 
Bladder
0.264 89.4 93.0 Rectum
0.514 66.5 73.3 Sigmoid
0.330 96.9 94.5 D90 CTV 
Conclusions: Bladder filling had various influence on the position of 
bladder, cervix and uterus in respect to each other, corresponding to 
the various uterine anatomies (retroversion or anteversion) and 
posture of bladder relative to surrounding organs. The few 
discrepancies in CTV volume between two planning was due to 
considering GEC-ESTRO and ICRU recommendations in contouring HR-
CTVs and movement of OARs between these two patient anatomy 
conditions. Decrease in average of dose parameters for OARs and 
Increase in D90 for empty bladders can be a good motivation to 
choose this status although statistical test couldn’t improve it. Having 
two series of CT data in empty/full condition, at least for the first 
fraction of BT, can act as guidance and give a useful vision of 
anatomical reactions in each situation, but compromising with patient 
dose. Study is in progress for more case analysis.  
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Purpose/Objective: To objectively evaluate the implementation of 
MR Image Based Brachytherapy in Cervical Cancers at our centre.  
Materials and Methods: The approach consists of reporting the 
retrospective analysis of dosimetric and clinical outcome of 24 
patients (RD experience) with prescription to point A followed by 
prospective data (PD Experience) with HR-CTV dose optimization, 
prescription and contribution to multicentric International EMBRACE 
study. The dosimetric data (EQD2 values) and clinical outcome for 
these groups were compared and evaluated further with respect to 
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GYN GEC – ESTRO Recommendations for MR Image Based 
Brachytherapy. 
Results: Dosimetric outcome: The mean + SD HR-CTV was 45.2 +15.8 
cc and 42.5 + 19.5 cc for RD and PD experience respectively. The 
mean + SD point A dose was 73.4+4.5 Gy in RD experience Vs 93 + 24.8 
Gy with PD experience. Similarly,the mean + SD D90 doses were 70.9 + 
10.6 Gy for RD Vs 87.2 +4.4 Gy for PD data. For OAR's, the mean + SD 
ICRU rectal and bladder points were 63.5 + 8.1 and 80.4 + 34.4 Gy 
respectively. The D2cc for rectum, bladder and sigmoid for RD data 
were 57.8 + 7.7 Gy, 93.4 +24.6 Gy and 74.6 + 19.6 Gy while it was 64 + 
5.5 Gy, 74.8 +7.1 Gy and 65.2 + 5.4 Gy respectively for PD set.  
Clinical Outcome: For RD experience, with a median follow-up of 24 
months, 3 patients had local failure, 1 had right external iliac nodal 
failure, and 1 left supraclavicular nodal failure whereas for PD 
experience with a median follow-up of 16 months, 3 had local 
recurrence,1 nodal, 4: loco-regional + distant and 3 patients had 
distant failures. All the local recurrences in both the RD and PD 
experience were HR-CTV infield relapses. In RD experience, 1 patient 
had Grade ¾ procto-sigmoiditis (Sigmoid 2cc : 140 Gy ) whereas so far 
no patient has been reported with significant late toxicity in PD 
experience. 
Conclusions: There is an overall significant improvement in 
therapeutic ratio in favour of PD experience. With the HR-CTV 
volumes being the same, the target volume doses are higher, doses to 
sigmoid and bladder are lower. The clinical outcome looks promising 
in terms of local control rates, however, longer follow-up is required 
to assess late sequelae. 
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Purpose/Objective: Three dimensional image-guided brachytherapy 
allows the assessment of the dose to organs at risk with Dose Volume 
Histograms (DVHs). The purpose of this study was to find a correlation 
between the DVHs and in-vivo dosimetry measurements for the 
bladder and rectum. 
Materials and Methods: During the period from 2009 to 2011, a total 
of 17 cervix carcinoma patients were treated with High Dose Rate 
brachytherapy (Ir-192). After the implantation of the catheter and 
previous to the treatment, the patients were CT scanned generating a 
total of 28 CT datasets. In-vivo dosimetry was performed 2 to 3 times 
on each patient using Thermo Luminescence Dosimeters of LiF (TLD-
100). The TLD rods were inserted in plastic tubes and separated with 
wires to facilitate their location on the CT scan. The tubes were 
introduced in urethral and rectal catheters inside the patient. The 
TLDs were calibrated every treatment day using the same Ir-192 
source that was used for the treatment. Protocols of annealing and 
read-out were followed to reduce uncertainties in dose measurements 
around brachytherapy sources. A retrospective study of these patients 
was performed after the acquisition of the brachytherapy dose 
planning system, OncentraR Brachy v4.0. The 28 CT datasets were 
imported in the dose planning system, the bladder and rectum 
delineated, a dose plan reproducing the received treatment was 
generated and the DVHs calculated. The minimum dose to 5cc, 2cc, 
1cc and 0.1cc tissue receiving the highest dose (D5cc, D2cc, D1cc and 
D0.1cc) was recorded and correlated to the maximum and average dose 
measured with the TLDs.  
Results: Statistically significant correlation (p<0.001) was found 
between the bladder volumetric doses (D5cc, D2cc, D1cc and D0.1cc) and 
the measured maximum and average dose. The correlation 
coefficients were 0.83, 0.85, 0.87 and 0.87 respectively for the 
maximum dose and 0.84, 0.86, 0.86 and 0.85 respectively for the 
average dose. For the rectal data no statistically significant 
correlation was found (p<0.3). The correlation coefficients were 0.39, 
0.39, 0.38, 0.34 respectively for the maximum dose and 0.15, 0.15, 
0.14, 0.13 respectively for the average dose. 
Conclusions: The significant correlation between the volumetric 
bladder doses and the measurements indicate that in-vivo dosimetry is 
an important method of quality assurance and could be used as a 
complement to the 3D image-guided brachytherapy. The lack of 
correlation in the rectal data might be due to the length of the rectal 
catheter that reached the sigmoid area when it was fully inserted. 
Therefore the rectal measurements correspond to the sigmoid dose 
and not to the rectal dose. As a result of this study we started to use 
a shorter catheter to assure that the TLDs are located at the rectum.  
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Purpose/Objective: HDR brachytherapy is widely used for tumor 
treatment. The main disadvantage is that using Ir-192 requires heavily 
shielded treatment room with an expensive remote control room. The 
main purpose of this work is to develop a HDR brachytherapy source 
that can be used in every regular hospital operation room without the 
need of very expensive treatment and control rooms.We have found 
Tm-170 to be a suitable isotope for that purpose. We have 
manufactured many Tm-170 seeds and we present here the results of 
animal experiments and dosimetry of those Tm-170 sources.  
Materials and Methods: Thulium-170 (Tm-170) is a radioactive isotope 
of half-life128 days, emitting photons in the range of 7-84 keV (~11% 
of the radiation emitted) and two beta rays of energy E max = 880 keV 
24%, and E max = 970 keV 76%. Many Tm-170 seeds for the LDR 
treatment were made and one source for the HDR treatment. The LDR 
seeds were made of thulium rectangles of dimensions: 4 x 0.6 x 0.2 
mm or cylindrical of 0.6 mm diameter, 4 mm long. The thulium was 
inserted into titanium sealed tube of 0.8 mm od, 0.7 mm id and 7 mm 
long. LDR experiments were done with seed activity in the range 0.5-
2.5 mCi. The HDR source was made of thulium cylinder 0.6 diameter 5 
mm long inside a titanium tube, all in a stainless steel tube of 1.2 mm 
od, 1.0 mm id. It was activated to about 5 Ci. Dosimetry of the Tm 
170 sources was done using a number of different methods and was 
calculated with Monte Carlo codes. TLD and film dosimetry were done 
in a Perspex phantom, in the range 4 – 30 mm from the source center. 
Measurements with LUDLUM NaI(Tl) dosimeter were done in air. 80 
BALB/C mice carrying KHJJ tumor were used in the LDR experiments 
and 12 Lewis rats carrying CNS1 Rat brain tumor were used in the HDR 
experiments 
Results: Survival of the treated animals is as follows: 60% of the 
treated mice were fully cured compared to none of the control, 75% 
of the rats were fully cured compared to none of the control. 
Dosimetry yielded the following results: The average of the many dose 
measurements of both the LDR seeds and the HDR source at 1 cm from 
the source (seed) in a Perspex phantom was 236 cGy/h Ci. That is 
about 20 times smaller than the dose from Ir-192 source at 1 cm. 
When theTm-170 seed is wrapped with 0.1 mm thick gold foil, to 
remove the beta radiation, the photon dose at 1 cm is reduced by a 
factor of 2.  
Conclusions: The survival of the treated animals is very encouraging, 
in particular for the HDR experiments. As for the dosimetry, Tm-170 
yields a lower photon dose at 1 cm from the source than Ir-192, 
however, if the beta radiation is acceptable, than the dose in the 
range up to 3 mm from the source is higher for Tm-170 than for Ir-
192. To avoid hot spots near the source the beta can be partly remove 
by wrapping the source with a thin gold coat. The Tm-170 activity 
should be higher and the seeds can be implanted at distances smaller 
than 1 cm. The benefit of avoiding heavy shielding worth the effort. 
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Purpose/Objective: Robust and relevant quality control (QC) is 
essential to ensure accuracy and safety in radiotherapy. QC in HDR 
brachytherapy has not kept pace with clinical modernisation e.g. 
volume-based prescriptions and patient-specific inverse-optimisation. 
New QC standards are required to confirm dose distribution accuracy 
and avoid errors. Typical QC is currently limited to straight catheters, 
point doses and well chambers. A 'state of the art' practical 
implementation of advanced multichannel film dosimetry is presented 
to verify delivered dose distributions around treatment applicators 
and sources. 3 cases are presented; a cervix ring applicator, a 
shielded vaginal cylinder, and an isolated source catheter. The 
application of gamma assessment criteria in brachytherapy is 
discussed. 
Materials and Methods: A film-array water phantom was used to 
accurately position Gafchromic EBT3 film, cut to 12 x 12 cm. 
Multichannel film dosimetry separating dose-dependent and dose-
